Drug Profile
ASP 9276
Alternative Names: ASP-9276Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Echinocandins
- Mechanism of Action Glucan synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Aspergillosis; Candidiasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Aspergillosis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Candidiasis in USA
- 12 Sep 2012 Preclinical trials in Aspergillosis in USA (unspecified route)